JP2008530137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530137A5 JP2008530137A5 JP2007555369A JP2007555369A JP2008530137A5 JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5 JP 2007555369 A JP2007555369 A JP 2007555369A JP 2007555369 A JP2007555369 A JP 2007555369A JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- skin
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65311405P | 2005-02-14 | 2005-02-14 | |
| US71676205P | 2005-09-13 | 2005-09-13 | |
| US74995205P | 2005-12-13 | 2005-12-13 | |
| PCT/US2006/005327 WO2006088955A2 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008530137A JP2008530137A (ja) | 2008-08-07 |
| JP2008530137A5 true JP2008530137A5 (enExample) | 2009-04-02 |
Family
ID=36685803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555370A Expired - Fee Related JP4927762B2 (ja) | 2005-02-14 | 2006-02-14 | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| JP2007555369A Pending JP2008530137A (ja) | 2005-02-14 | 2006-02-14 | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555370A Expired - Fee Related JP4927762B2 (ja) | 2005-02-14 | 2006-02-14 | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (11) | US20060188499A1 (enExample) |
| EP (2) | EP1856150A2 (enExample) |
| JP (2) | JP4927762B2 (enExample) |
| AU (2) | AU2006214326B2 (enExample) |
| CA (2) | CA2595939C (enExample) |
| IL (3) | IL184734A (enExample) |
| MX (2) | MX2007009471A (enExample) |
| WO (2) | WO2006088955A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1188830T3 (da) | 1999-06-02 | 2010-04-26 | Chugai Pharmaceutical Co Ltd | Nyt hæmopoietinreceptorprotein NR10 |
| EP1221482B1 (en) | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
| RU2490276C2 (ru) | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
| ES2579758T3 (es) * | 2005-01-28 | 2016-08-16 | Zymogenetics, Inc. | Preparaciones homogéneas de IL-31 |
| JP4927762B2 (ja) | 2005-02-14 | 2012-05-09 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| EP1858924A1 (en) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| CN101198624B (zh) | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| EP2001906A2 (en) | 2006-01-10 | 2008-12-17 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| ES2544888T3 (es) | 2006-06-08 | 2015-09-04 | Chugai Seiyaku Kabushiki Kaisha | Prevención o remedio para enfermedades inflamatorias |
| EP2061811A2 (en) | 2006-09-01 | 2009-05-27 | ZymoGenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| AU2008204823A1 (en) * | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| CA2708065C (en) | 2007-12-05 | 2015-02-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
| SI2796466T1 (en) | 2007-12-07 | 2018-01-31 | Zymogenetics, Inc. | Molecules of Humanized Specifics Specifiable for IL-31 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TW201537175A (zh) * | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| FI3284480T3 (fi) * | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| US10060273B2 (en) | 2015-04-15 | 2018-08-28 | United Technologies Corporation | System and method for manufacture of abrasive coating |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| CA3093709C (en) | 2018-03-16 | 2024-03-26 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン３１モノクローナル抗体 |
| CN112533675A (zh) * | 2018-04-25 | 2021-03-19 | 基尼克萨制药有限公司 | 通过递送抗OSMRβ抗体治疗皮肤疾病或病症 |
| CN117018202A (zh) * | 2019-07-08 | 2023-11-10 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| RU2707181C1 (ru) * | 2019-08-15 | 2019-11-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗ｉｌ３１抗体 |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
| KR102392954B1 (ko) * | 2020-02-11 | 2022-05-02 | 연세대학교 산학협력단 | 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도 |
| CA3189847A1 (en) | 2020-09-01 | 2022-03-10 | Naoki Fukazawa | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| EP1426059A4 (en) | 2001-09-14 | 2007-01-17 | Ono Pharmaceutical Co | DRUGS FOR TREATING PRURIT |
| WO2004003140A2 (en) * | 2002-01-18 | 2004-01-08 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
| RU2490276C2 (ru) * | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| JP2004219390A (ja) * | 2002-02-22 | 2004-08-05 | Taisho Pharmaceut Co Ltd | アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法 |
| WO2003070252A1 (fr) | 2002-02-22 | 2003-08-28 | Taisho Pharmaceutical Co., Ltd. | Agents antiprurigineux |
| JP2004107209A (ja) * | 2002-09-13 | 2004-04-08 | Nippon Oruganon Kk | 掻痒治療薬 |
| JP4503942B2 (ja) * | 2003-06-11 | 2010-07-14 | 大正製薬株式会社 | 止痒剤 |
| EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
| ES2579758T3 (es) | 2005-01-28 | 2016-08-16 | Zymogenetics, Inc. | Preparaciones homogéneas de IL-31 |
| JP4927762B2 (ja) | 2005-02-14 | 2012-05-09 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| CN101198624B (zh) * | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| WO2007037137A1 (ja) * | 2005-09-28 | 2007-04-05 | Konica Minolta Opto, Inc. | 射出成形装置 |
| EP2001906A2 (en) * | 2006-01-10 | 2008-12-17 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| EP2061811A2 (en) * | 2006-09-01 | 2009-05-27 | ZymoGenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| AU2008204823A1 (en) | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| SI2796466T1 (en) * | 2007-12-07 | 2018-01-31 | Zymogenetics, Inc. | Molecules of Humanized Specifics Specifiable for IL-31 |
-
2006
- 2006-02-14 JP JP2007555370A patent/JP4927762B2/ja not_active Expired - Fee Related
- 2006-02-14 WO PCT/US2006/005327 patent/WO2006088955A2/en not_active Ceased
- 2006-02-14 US US11/353,427 patent/US20060188499A1/en not_active Abandoned
- 2006-02-14 AU AU2006214326A patent/AU2006214326B2/en not_active Ceased
- 2006-02-14 JP JP2007555369A patent/JP2008530137A/ja active Pending
- 2006-02-14 CA CA2595939A patent/CA2595939C/en not_active Expired - Fee Related
- 2006-02-14 MX MX2007009471A patent/MX2007009471A/es not_active Application Discontinuation
- 2006-02-14 AU AU2006214325A patent/AU2006214325B2/en not_active Ceased
- 2006-02-14 EP EP06735136A patent/EP1856150A2/en not_active Withdrawn
- 2006-02-14 EP EP06735137.9A patent/EP1856539B1/en not_active Expired - Lifetime
- 2006-02-14 CA CA002595877A patent/CA2595877A1/en not_active Abandoned
- 2006-02-14 MX MX2007009577A patent/MX2007009577A/es active IP Right Grant
- 2006-02-14 US US11/353,454 patent/US20060188500A1/en not_active Abandoned
- 2006-02-14 WO PCT/US2006/005328 patent/WO2006088956A2/en not_active Ceased
-
2007
- 2007-07-19 IL IL184734A patent/IL184734A/en not_active IP Right Cessation
- 2007-07-23 IL IL184776A patent/IL184776A/en not_active IP Right Cessation
-
2008
- 2008-09-26 US US12/239,107 patent/US7723048B2/en not_active Expired - Lifetime
-
2009
- 2009-07-02 US US12/497,383 patent/US20090280121A1/en not_active Abandoned
-
2010
- 2010-03-19 US US12/727,912 patent/US8435745B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 US US13/094,482 patent/US8388964B2/en not_active Expired - Fee Related
-
2012
- 2012-04-15 IL IL219145A patent/IL219145A0/en unknown
-
2013
- 2013-01-30 US US13/754,278 patent/US20130177563A1/en not_active Abandoned
- 2013-03-13 US US13/799,048 patent/US8926957B2/en not_active Expired - Lifetime
-
2015
- 2015-10-09 US US14/879,550 patent/US20160024201A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,774 patent/US20170096484A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,883 patent/US20190040125A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Calcinotto et al. | Cellular senescence: aging, cancer, and injury | |
| JP2008530138A5 (enExample) | ||
| US11446398B2 (en) | Regulated biocircuit systems | |
| JP2020022469A (ja) | 血中循環腫瘍細胞に関する方法およびアッセイ | |
| BR112014010161A2 (pt) | anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43 | |
| KR20200106053A (ko) | Atr 억제제를 사용한 암 치료 방법 | |
| AU2019339469A1 (en) | Novel LILRB4 antibodies and uses thereof | |
| RU2013153592A (ru) | Анти-mif антитела | |
| US11059906B2 (en) | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma | |
| KR20220042056A (ko) | 골수성 세포 염증성 표현형을 조절하기 위한 항-siglec-9 조성물 및 방법, 그리고 이의 용도 | |
| KR20220042055A (ko) | 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도 | |
| Diao et al. | Telomeric epigenetic response mediated by Gadd45a regulates stem cell aging and lifespan | |
| JP2017506505A5 (enExample) | ||
| AU2005265067B2 (en) | Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors | |
| Kim et al. | Hedgehog signaling is associated with liver response to fractionated irradiation in mice | |
| WO2010036031A3 (en) | Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same | |
| Dou et al. | Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR‐Mediated JAK/STAT Signaling and Immune Modulation | |
| CN102641501B (zh) | Nalp3-asc炎症复合体及其激活抑制剂在制备朊病毒病药物中的应用 | |
| Mahmoud et al. | Aptabinding of tumor necrosis factor‐α (TNFα) inhibits its proinflammatory effects and alleviates islet inflammation | |
| TWI672319B (zh) | 用於確認、預測以及治療癌症的方法 | |
| Zhang et al. | Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis | |
| HK1208819A1 (en) | Anti-ccl2 antibodies for treatment of scleroderma | |
| KR102202120B1 (ko) | 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도 | |
| Li et al. | The m6A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis | |
| SCHREIBER | RESTORATION OF TRANSCRIPTIONALLY ACTIVE CHROMATIN AT FXN IN FRDA iPSC-DIFFERENTIATED NEURON PROGENITOR CELLS FOLLOWING PHARMACOLOGICAL INTERVENTION |